Media coverage
2
Media coverage
Title Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis; Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis. Media name/outlet CancerNetwork Country/Territory United States Date 12/12/24 Persons John Mascarenhas Title Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis Media name/outlet Cancernetwork.com Country/Territory United States Date 12/12/24 URL ct.moreover.com/?a=55529046545&p=1gw&v=1&x=x8t81e2cfGA9iQvhZH0p7g Persons John Mascarenhas